RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis
详细信息 查看全文
- 作者：Adam M. Kruszewskia ; Gautam Raoa ; Alexandru Tatomira ; Daniel Hewesa ; Cosmin A. Teglaa ; b ; Cornelia D. Cudricia ; Vingh Nguyenc ; Walter Royal IIIa ; d ; Christopher T. Bever Jra ; b ; d ; Violeta Rusc ; Horea Rusa ; b ; d ; hrus@umaryland.edu" class="auth_mail" title="E-mail the corresponding author
- 关键词：AKT ; AKT8 virus oncogene cellular homolog ; AUC ; area under the curve ; CDC2 ; cell division cycle protein 2 homolog ; CNS ; central nervous system ; CPT ; cell preparation tubes ; EDSS ; expanded disability status scale ; FasL ; Fas ligand ; GA ; glatiramer acetate ; IL ; interleukin ; MRI ; magnetic resonance imaging ; MS ; multiple sclerosis ; NRV ; normalized mRNA value ; PBMCs ; peripheral blood mononuclear cells ; RGC ; response gene to complement ; ROC ; receiver operating characteristic ; RRMS ; relapsing-remitting
- 刊名：Experimental and Molecular Pathology
- 出版年：2015
- 出版时间：December 2015
- 年：2015
- 卷：99
- 期：3
- 页码：498-505
- 全文大小：1274 K
文摘
- •
The role of RGC-32 as a biomarker of response to treatment was investigated.
- •
RGC-32 was found to be a biomarker of response to glatiramer acetate treatment.
- •
RGC-32 was found to be a biomarker of clinical activity in multiple sclerosis.
- •
FasL and IL-21 were also found to be biomarkers of response to GA treatment.